Thomas Matthew Habermann, MD

  • 21571 Citations
  • 77 Scopus h-Index
1978 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Thomas Matthew Habermann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 31 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Lymphoma Specialized Program of Research Excellence

Macon, W. R., Dogan, A. M., Ansell, S. M., Gupta, M. D., Witzig, T. E., Cerhan, J. R., Habermann, T. M., Ratliff, T. L., Link, B. K., Ratliff, T. L., Juweid, M., Ballas, Z., Link, B. K., Ratliff, T., Geyer, S. M., Weiner, G., Lentz, S., Hohl, R., Smith, B. J., Kaufmann, S. H., Feldman, A. L. & Witzig, T. E.

National Institutes of Health

9/11/026/30/17

Project: Research project

  • EASTERN COOPERATIVE ONCOLOGY GROUP

    Habermann, T. M., Hahn, R. & Edmonson, J.

    National Institutes of Health

    6/1/784/30/16

    Project: Research project

  • Research Output

    Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease

    Goyal, G., Ravindran, A., Young, J. R., Shah, M. V., Bennani, N. N., Patnaik, M. M., Nowakowski, G. S., Thanarajasingam, G., Habermann, T. M., Vassallo, R., Sher, T., Parikh, S. A., Rech, K. L. & Go, R. S., Jan 31 2020, In : Haematologica. 105, 2, p. 348-357 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • 3 Scopus citations

    Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma

    St-Pierre, F., Broski, S. M., LaPlant, B. R., Maurer, M. J., Ristow, K., Thanarajasingam, G., Macon, W. R., Habermann, T. M. & Witzig, T. E., Jan 1 2020, (Accepted/In press) In : Oncologist.

    Research output: Contribution to journalArticle

    Open Access
  • High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?

    Pophali, P. A., Marinelli, L. M., Ketterling, R. P., Meyer, R. G., McPhail, E. D., Kurtin, P. J., Mwangi, R., Maurer, M. J., Habermann, T. & King, R. L., Jan 1 2020, In : Blood cancer journal. 10, 1, 5.

    Research output: Contribution to journalArticle

    Open Access
  • Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients

    Jakobsen, L. H., Ellin, F., Smeland, K. B., Wästerlid, T., Christensen, J. H., Jørgensen, J. M., Josefsson, P. L., Øvlisen, A. K., Holte, H., Blaker, Y. N., Grauslund, J. H., Bjørn, J., Molin, D., Lagerlöf, I., Smedby, K. E., Colvin, K., Thanarajasingam, G., Maurer, M. J., Habermann, T. M., Song, K. W. & 4 others, Zhu, K. Y., Gerrie, A. S., Cheah, C. Y. & El-Galaly, T. C., Jan 1 2020, (Accepted/In press) In : British journal of haematology.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?

    Novo, M., Nowakowski, G. S., Habermann, T. M., Witzig, T. E., Micallef, I. N., Johnston, P. B., Inwards, D. J., Botto, B., Ristow, K. M., Young, J. R., Vitolo, U. & Ansell, S. M., Jan 28 2020, In : Leukemia and Lymphoma. 61, 2, p. 318-327 10 p.

    Research output: Contribution to journalArticle